June 12, 2018
Authored and Edited by Andrew Q. Leba; Thomas L. Irving
On May 31, 2018, FDA issued draft guidance on Formal Meetings Between the FDA and Sponsors or Applicants of Biosimilar User Fee Act (BsUFA) Products. The draft guidance provides background indicating that, each year, FDA review staff holds many formal meetings with sponsors seeking advice regarding the development and review of biosimilar or interchangeable products regulated by the CDER or the CBER. Because these formal meetings often represent critical points in the regulatory and development process, the draft guidance seeks to provide recommendations to sponsors on how to hold formal meetings with the FDA regarding the development and review of biosimilar or interchangeable products. Specifically, the guidance discusses the principles of good meeting management practices (GMMPs) and describes consistent, standardized procedures that promote well-managed meetings and ensures that such meetings are scheduled within a reasonable time, conducted efficiently, and documented appropriately.
The draft guidance identifies the five types of formal meetings that occur between sponsors and FDA staff to discuss a biosimilar or interchangeable product and describes important procedures for each meeting:
The draft guidance further discusses general considerations for holding formal meetings with the FDA including describing BsUFA fees associated with the formal meetings, describing meeting formats via face to face, teleconference/videoconference, or written response only, outlining procedures to request a meeting with the FDA, detailing procedures for denying and granting meetings, specifying communications before meetings, rescheduling meetings, cancelling meetings, guidelines for meeting conduct, and general considerations regarding documentation of meeting minutes.
The draft guidance further outlines meeting package content requirements to facilitate FDA review. For example, the guidance recommends that the meeting package should provide information relevant to the product, stage of development, and meeting type requested. The guidance further recommends that the meeting package contain enough detail to meet the meeting objectives, e.g., inclusion of raw data to support the derived conclusions in the package. The guidance further warns that simply describing a result as “significant” without support is insufficient information for the FDA review division to give good advice or identify important problems the sponsor may have missed. The guidance finally lists sixteen pieces of information such as application number and proposed indications that should be included in each meeting package.
Readers are encouraged to read the draft guidance, also available on FDA’s website.
Food and Drug Administration (FDA), FDA Guidance, Biologic License Application (BLA), abbreviated biologic license application (aBLA), Biologics Price Competition and Innovation Act (BPCIA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.